ADVANZ PHARMA Responds to OCALIVA® Revocation
ADVANZ PHARMA Holdco Limited, a well-known player in the pharmaceutical industry, has made a significant statement regarding the recent revocation of the conditional marketing authorization (CMA) for OCALIVA® in Europe by the European Commission. OCALIVA® is the only approved farnesoid X receptor (FXR) agonist available for treating patients with the rare disease Primary Biliary Cholangitis (PBC).
Consequences of the European Commission's Decision
With OCALIVA® being the only second-line treatment option previously accessible, the European Commission's decision places many patients battling PBC at an increased risk of their disease worsening. ADVANZ PHARMA is currently exploring all possible options to ensure that these patients can continue to access OCALIVA®.
Steffen Wagner, the CEO, expressed that this decision undermines years of progress in treatment for thousands of patients who have benefited from OCALIVA®. The company is committed to working closely with all relevant EU authorities to keep this essential treatment available.
The Role of OCALIVA® in PBC Treatment
Since its conditional approval in December 2016, OCALIVA® has served as the only effective second-line treatment option for PBC patients in Europe. This medication offers a unique mechanism of action, which is vital given the limited treatment options for this serious autoimmune disease.
Supporting Evidence for OCALIVA®
ADVANZ PHARMA contends that the CHMP's recommendation to revoke the CMA did not adequately take into account the extensive real-world evidence demonstrating OCALIVA®'s efficacy and safety. This evidence encompasses over seven years and includes treatment data from more than 47,000 patient-years, yet the recommendation primarily relied on a single randomized placebo-controlled trial that had significant limitations.
Backing from Healthcare Communities
The withdrawal of OCALIVA® has sparked concerns among patients, healthcare professionals, and scientific organizations. Many emphasize that OCALIVA® remains a crucial second-line treatment in current clinical guidelines, highlighting its importance in managing this life-threatening condition. The EMA has also indicated that ADVANZ PHARMA could, in accordance with local regulations, continue to provide OCALIVA® on a compassionate basis or through named patient programs.
Commitment to Supporting Patients
ADVANZ PHARMA is dedicated to patient support and ensuring that OCALIVA® remains accessible in line with national regulations. They encourage patients with concerns to reach out to their healthcare providers without delay.
Overview of OCALIVA® and PBC
Primary Biliary Cholangitis (PBC) is a serious progressive autoimmune disorder that damages the bile ducts in the liver. OCALIVA® is a film-coated tablet containing obeticholic acid, an effective FXR agonist that plays a crucial role in regulating various physiological pathways in the liver.
About ADVANZ PHARMA
As a global pharmaceutical company, ADVANZ PHARMA is focused on improving patients' lives by providing specialty and rare disease medications. The company operates in over 90 countries and is committed to developing and commercializing innovative medicines across a range of therapeutic areas.
Frequently Asked Questions
What is the significance of OCALIVA® for PBC patients?
OCALIVA® is the only approved second-line treatment for PBC, making it essential for patients whose conditions have not sufficiently responded to other therapies.
What actions is ADVANZ PHARMA taking in response to the withdrawal?
ADVANZ PHARMA is looking into all available options to ensure that patients can continue to access OCALIVA® and is committed to collaborating with regulatory authorities.
How has the medical community reacted to the decision?
There is considerable concern among healthcare professionals and scientific societies regarding the implications of the EC’s decision, with many advocating for the ongoing availability of OCALIVA®.
What evidence supports the safety and efficacy of OCALIVA®?
ADVANZ PHARMA highlights that over seven years of real-world evidence supports the use of the medication, despite the EC's reliance on limited trial data.
Who should patients contact for more information?
Patients are advised to consult their treating physician for any questions or concerns about their treatment options and access to OCALIVA®.
